Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 13/20 | 0.47 |
| ▸ | MMP12 | P39900 | 5/20 | 0.46 |
| ▸ | MMP2 | P08253 | 6/20 | 0.43 |
| ▸ | MMP3 | P08254 | 5/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 4/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942640 | 0.88 | MMP13 (0.58) | MMP13MMP12MMP2MMP14ADAMTS5 | |
| SCHEMBL8272987 | 0.88 | MMP13 (0.47) | MMP13MMP12MMP14 | |
| SCHEMBL6920418 | 0.86 | MMP13 (0.42) | MMP13MMP12MMP2MMP3MMP14 | |
| SCHEMBL6920415 | 0.86 | MMP13 (0.42) | MMP13MMP12MMP2MMP3MMP14 | |
| SCHEMBL7158166 | 0.86 | MMP13 (0.42) | MMP13MMP12MMP2MMP3MMP14 | |
| SCHEMBL941447 | 0.82 | MMP13 (0.55) | MMP13MMP12MMP14 | |
| SCHEMBL6922996 | 0.80 | GPR119 (0.43) | MMP13MMP12MMP2MMP3MMP14 | |
| SCHEMBL6926427 | 0.78 | MMP13 (0.44) | MMP13MMP12MMP14 | |
| SCHEMBL8133854 | 0.78 | MMP13 (0.42) | MMP13MMP12MMP2MMP3MMP14 | |
| SCHEMBL8149989 | 0.77 | MMP13 (0.40) | MMP13MMP12MMP2MMP3MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004024718-A1 | IMIDAZOLIDINEDIONE-DERIVATIVES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | claimed |